Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Clinical trial NCT07486713 · RECRUITING

Trial details

NCT number: NCT07486713
Sponsor: Rigel Pharmaceuticals
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

AML (Acute Myeloid Leukemia)Glioma Cholangiocarcinoma Solid Tumor Malignancies

Start date: 2026-02-23
Primary completion: 2027-04-30
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.